November 6, 2024 10:34 AM EST
News Briefing

Macro­Gen­ics paus­es de­vel­op­ment of ADC; Cel­lec­tis de­pri­or­i­tizes CAR-T

ENDPOINTS

Plus, news about Tan­go Ther­a­peu­tics, En­do, Neu­ro­gene and Cen­tu­ry Ther­a­peu­tics:

Macro­Gen­ics stopped dos­ing pa­tients in ADC tri­al: Af­ter three pa­tient deaths in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times